Literature DB >> 26327482

High Risk of Diabetes and Neurobehavioral Deficits in Individuals With Surgically Treated Hyperinsulinism.

Katherine Lord1, Jerilynn Radcliffe1, Paul R Gallagher1, N Scott Adzick1, Charles A Stanley1, Diva D De León1.   

Abstract

CONTEXT: Children with the most common and severe type of congenital hyperinsulinism (HI) frequently require pancreatectomy to control the hypoglycemia. Pancreatectomy increases the risk for diabetes, whereas recurrent hypoglycemia places children at risk of neurocognitive dysfunction. The prevalence of these complications is not well defined.
OBJECTIVE: The objective was to determine the prevalence of diabetes and neurobehavioral deficits in surgically treated HI.
DESIGN: This was designed as a cross-sectional study of individuals who underwent pancreatectomy for HI between 1960 and 2008. OUTCOMES: Diabetes outcomes were assessed through patient interview and medical record review. Neurobehavioral outcomes were assessed through the Adaptive Behavior Assessment System, 2nd edition (ABAS-II), and the Child Behavior Checklist (CBCL).
RESULTS: A total of 121 subjects were enrolled in the study at a median age of 8.9 years (range, 3.5-50.7 y). Thirty-six percent (44 of 121) of subjects had diabetes. Nine subjects developed diabetes immediately after pancreatectomy. Of the remaining 35 subjects who developed diabetes, the median age at diabetes diagnosis was 7.7 years (range, 8 mo to 43 y). In subjects with diabetes, the median hemoglobin A1c was 7.4% (range, 6.5-12.6%), and 38 (86%) subjects required insulin. Subjects with diabetes had a greater percentage of pancreatectomy than subjects without diabetes (95% [range, 65-98] vs 65% [1-98]). Neurobehavioral abnormalities were reported in 58 (48%) subjects. Nineteen (28%) subjects had abnormal ABAS-II scores, and 10 (16%) subjects had abnormal CBCL scores.
CONCLUSIONS: Children, who undergo near-total pancreatectomy are at high risk of developing diabetes. Neurobehavioral deficits are common, and developmental assessment is essential for children with HI.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26327482      PMCID: PMC4702456          DOI: 10.1210/jc.2015-2539

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy.

Authors:  P de Lonlay; J C Fournet; J Rahier; M S Gross-Morand; F Poggi-Travert; V Foussier; J P Bonnefont; M C Brusset; F Brunelle; J J Robert; C Nihoul-Fékété; J M Saudubray; C Junien
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy.

Authors:  P Thomas; Y Ye; E Lightner
Journal:  Hum Mol Genet       Date:  1996-11       Impact factor: 6.150

3.  The basic structural lesion of persistent neonatal hypoglycaemia with hyperinsulinism: deficiency of pancreatic D cells or hyperactivity of B cells?

Authors:  J Rahier; K Fält; H Müntefering; K Becker; W Gepts; S Falkmer
Journal:  Diabetologia       Date:  1984-04       Impact factor: 10.122

4.  Growth and development in patients operated on for islet cell dysplasia.

Authors:  D G Jacobs; K Haka-Ikse; D E Wesson; R M Filler; G Sherwood
Journal:  J Pediatr Surg       Date:  1986-12       Impact factor: 2.545

Review 5.  Hyperinsulinism in infants and children: diagnosis and therapy.

Authors:  C A Stanley; L Baker
Journal:  Adv Pediatr       Date:  1976

6.  Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up.

Authors:  G Leibowitz; B Glaser; A A Higazi; M Salameh; E Cerasi; H Landau
Journal:  J Clin Endocrinol Metab       Date:  1995-02       Impact factor: 5.958

7.  Long-term follow-up of 114 patients with congenital hyperinsulinism.

Authors:  Thomas Meissner; Udo Wendel; Peter Burgard; Silvia Schaetzle; Ertan Mayatepek
Journal:  Eur J Endocrinol       Date:  2003-07       Impact factor: 6.664

8.  Long-term follow-up of patients with congenital hyperinsulinism in Austria.

Authors:  Saadet Mercimek-Mahmutoglu; Birgit Rami; Martha Feucht; Marion Herle; Olaf Rittinger; Sylvia Stoeckler-Ipsiroglu; Edith Schober
Journal:  J Pediatr Endocrinol Metab       Date:  2008-06       Impact factor: 1.634

9.  Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism.

Authors:  Jacques Beltrand; Marylène Caquard; Jean-Baptiste Arnoux; Kathleen Laborde; Gilberto Velho; Virginie Verkarre; Jacques Rahier; Francis Brunelle; Claire Nihoul-Fékété; Jean-Marie Saudubray; Jean-Jacques Robert; Pascale de Lonlay
Journal:  Diabetes Care       Date:  2011-12-21       Impact factor: 19.112

10.  Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism.

Authors:  Ved Bhushan Arya; Senthil Senniappan; Huseyin Demirbilek; Syeda Alam; Sarah E Flanagan; Sian Ellard; Khalid Hussain
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

View more
  40 in total

Review 1.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 2.  Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders.

Authors:  Charles A Stanley
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

3.  Functional and Metabolomic Consequences of KATP Channel Inactivation in Human Islets.

Authors:  Changhong Li; Amanda M Ackermann; Kara E Boodhansingh; Tricia R Bhatti; Chengyang Liu; Jonathan Schug; Nicolai Doliba; Bing Han; Karen E Cosgrove; Indraneel Banerjee; Franz M Matschinsky; Itzhak Nissim; Klaus H Kaestner; Ali Naji; N Scott Adzick; Mark J Dunne; Charles A Stanley; Diva D De León
Journal:  Diabetes       Date:  2017-04-25       Impact factor: 9.461

Review 4.  Congenital hyperinsulinism disorders: Genetic and clinical characteristics.

Authors:  Elizabeth Rosenfeld; Arupa Ganguly; Diva D De Leon
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-08-14       Impact factor: 3.908

Review 5.  Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties.

Authors:  Arianna Maiorana; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2017-06-27       Impact factor: 4.982

6.  ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes.

Authors:  Karen A Landmeier; Monica Lanning; David Carmody; Siri Atma W Greeley; Michael E Msall
Journal:  Pediatr Diabetes       Date:  2016-08-24       Impact factor: 4.866

Review 7.  Genetic characteristics of patients with congenital hyperinsulinism.

Authors:  Mary Ellen Vajravelu; Diva D De León
Journal:  Curr Opin Pediatr       Date:  2018-08       Impact factor: 2.856

8.  Congenital Hypoglycemia Disorders: New Aspects of Etiology, Diagnosis, Treatment and Outcomes: Highlights of the Proceedings of the Congenital Hypoglycemia Disorders Symposium, Philadelphia April 2016.

Authors:  Diva D De Leon; Charles A Stanley
Journal:  Pediatr Diabetes       Date:  2016-10-18       Impact factor: 4.866

9.  A unique allosteric insulin receptor monoclonal antibody that prevents hypoglycemia in the SUR-1-/- mouse model of KATP hyperinsulinism.

Authors:  Puja Patel; Lawrenshey Charles; John Corbin; Ira D Goldfine; Kirk Johnson; Paul Rubin; Diva D De León
Journal:  MAbs       Date:  2018-06-01       Impact factor: 5.857

10.  Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.

Authors:  Chee M Ng; Fei Tang; Steven H Seeholzer; Yixuan Zou; Diva D De León
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.